- Home
- PYN vs LSTA Comparison
PYN vs LSTA Comparison
Compare PYN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- LSTA
- Stock Information
- Founded
- PYN 2002
- LSTA 1980
- Country
- PYN United States
- LSTA United States
- Employees
- PYN N/A
- LSTA N/A
- Industry
- PYN Investment Managers
- LSTA Misc Health and Biotechnology Services
- Sector
- PYN Finance
- LSTA Health Care
- Exchange
- PYN Nasdaq
- LSTA Nasdaq
- Market Cap
- PYN 33.5M
- LSTA 31.2M
- IPO Year
- PYN N/A
- LSTA N/A
- Fundamental
- Price
- PYN $5.81
- LSTA $2.51
- Analyst Decision
- PYN
- LSTA Strong Buy
- Analyst Count
- PYN 0
- LSTA 1
- Target Price
- PYN N/A
- LSTA $15.00
- AVG Volume (30 Days)
- PYN 19.9K
- LSTA 58.9K
- Earning Date
- PYN 01-01-0001
- LSTA 02-27-2025
- Dividend Yield
- PYN 5.07%
- LSTA N/A
- EPS Growth
- PYN N/A
- LSTA N/A
- EPS
- PYN N/A
- LSTA N/A
- Revenue
- PYN N/A
- LSTA N/A
- Revenue This Year
- PYN N/A
- LSTA N/A
- Revenue Next Year
- PYN N/A
- LSTA N/A
- P/E Ratio
- PYN N/A
- LSTA N/A
- Revenue Growth
- PYN N/A
- LSTA N/A
- 52 Week Low
- PYN $4.84
- LSTA $2.19
- 52 Week High
- PYN $6.60
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- PYN 53.96
- LSTA 40.33
- Support Level
- PYN $5.72
- LSTA $2.51
- Resistance Level
- PYN $5.89
- LSTA $2.66
- Average True Range (ATR)
- PYN 0.04
- LSTA 0.19
- MACD
- PYN 0.01
- LSTA -0.01
- Stochastic Oscillator
- PYN 55.22
- LSTA 17.50
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.